IC
KPTI icon

Ikarian Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Ikarian Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.12M Buy
+920,000
New +$7.01M 0.42% 59
2020
Q2 		– Sell
-36,787
Closed -$10.6M – 193
2020
Q1 		$10.6M Buy
36,787
+23,447
+176% +$6.47M 0.8% 31
2019
Q4 		$3.84M Buy
+13,340
New +$2.89M 0.62% 44

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Ikarian Capital's KPTI Position: Q1 2026 in Review

Ikarian Capital increased its Karyopharm Therapeutics (KPTI) stake by 35% in Q1 2026, buying an estimated $1.44M and bringing the position to 733,435 shares worth $4.09M. The position accounts for 0.33% of the portfolio, ranked #68.

Ikarian Capital first reported a position in KPTI in Q1 2020 and has held it in 18 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Ikarian Capital held 733,435 shares of Karyopharm Therapeutics worth $4.09M as of Q1 2026.
  • Ikarian Capital bought 188,881 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.44M.
  • Karyopharm Therapeutics made up 0.33% of Ikarian Capital's portfolio in Q1 2026, its #68 holding.
  • Ikarian Capital first reported a position in Karyopharm Therapeutics in Q1 2020 and has held it in 18 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.